The ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) demonstrated that inclisiran, an siRNA therapeutic that targets protease proprotein convertase subtilisin/ kexin type 9 mRNA within hepatocytes, produces significant low-density lipoprotein cholesterol reduction. The effects of inclisiran on other lipids are less well described.
M
onoclonal antibodies (mAbs) to the serine protease PCSK9 (proprotein convertase subtilisin/ kexin type 9) have been shown to incrementally reduce low-density lipoprotein cholesterol (LDL-C) by ≈50% to 60% over and above statins and to reduce cardiovascular events proportional to the magnitude of the absolute reduction in LDL-C and duration of exposure. [1] [2] [3] [4] Despite the tremendous promise of this new class of drugs, the high costs of mAbs, combined with the need for subcutaneous administration every 2 or 4 weeks, have fueled the search for alternative methods to inhibit PCSK9. Inclisiran is a chemically modified small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine that inhibits PCSK9 synthesis by specifically targeting PCSK9 mRNA in hepatocytes. The primary results of the ORION-1 trial (Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol [LDL-C]) of inclisiran have been previously reported. 5 In brief, ORION-1 assessed 6 possible starting regimens (3 single-dose and 3 two-dose starting regimens administered 90 days apart). The design of the study was such that LDL-C measurements were continued through 1 year to assess the dosing interval for the maintenance phase. ORION-1 confirmed the feasibility of achieving LDL-C reductions of a magnitude broadly similar to that of PCSK9 mAbs with substantially fewer injections.
PCSK9-inhibiting mAbs sequester virtually all circulating PCSK9 but do not influence intracellular pathways. Various lines of evidence indicate that targeting PCSK9 intracellularly such as with inclisiran may produce effects on lipid and lipoprotein metabolism beyond those that can be achieved with mAbs. 6 For example, animal studies and human lipoprotein kinetic studies in individuals with PCSK9 mutations suggested that PCKS9 may affect apolipoprotein (apo) B synthesis rates, whereas human kinetic studies with mAbs (targeting circulating PCSK9) revealed that these drugs do not alter hepatic apo B production. [7] [8] [9] [10] An in-depth evaluation of the effect of inclisiran on lipids and lipoproteins beyond LDL-C could provide insights into whether clinically meaningful differences exist between intracellular and extracellular approaches to PCSK9 inhibition.
This report from the ORION-1 trial describes in detail the effect of inclisiran on prespecified secondary lipid and lipoprotein outcomes over time, for up to 210 days, as well as the individual variation in response in these measures.
METHODS
The study design and the primary outcomes of the ORION-1 trial (https://www.clinicaltrials.gov, identifier NCT02597127) have been previously reported. 5 In brief, ORION-1 was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy, safety, and tolerability of inclisiran at various doses in 501 patients with established atherosclerotic cardiovascular disease (ASCVD) or risk equivalents and with elevated LDL-C despite receiving the maximum tolerated dose of a statin. Two different starting regimens were assessed. Participants received a single dose of placebo or inclisiran 200, 300, or 500 mg or 2 doses (at days 1 and 90) of placebo or inclisiran 100, 200, or 300 mg. The primary efficacy outcome measure was the percentage change from baseline in LDL-C at day 180. Secondary end points included the percentage change in other lipids and lipoproteins at day 180 and the time course through day 210, as well as interindividual response variation and the proportion of patients who attained lipid modification goals for their level of ASCVD risk. 5 Ethics committee approval was obtained at all participating institutions, and all participants gave written informed consent. The data, analytical methods, and study materials will not be made available to other researchers for the purposes of reproducing the results or replicating the procedure. However, we encourage parties interested in collaboration What Are the Clinical Implications?
• Inhibiting the synthesis of protease proprotein convertase subtilisin/kexin type 9 through siRNA may be a viable alternative to monoclonal antibodies with respect to effects on atherogenic lipoproteins.
• A starting regimen of 300 mg administered at days 1 and 90 provided the greatest reduction and the most prolonged effect on atherogenic lipoproteins, which may enable a convenient biannual dosing regimen during the subsequent maintenance phase.
• A starting regimen of 300 mg inclisiran administered 90 days apart resulted in modest variability in the effects on apolipoprotein B and non-highdensity lipoprotein cholesterol.
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and data sharing to contact the corresponding author directly for further discussions. All laboratory analyses were performed on fasting blood samples at Medpace Reference Laboratories, which were accredited by the National Heart, Lung, and Blood Institute Part III Lipid Standardization Program. Total cholesterol and triglyceride concentrations were measured with enzyme-based colorimetric assays on a Beckman Coulter AU series automatic analyzer with calibration directly traceable to Centers for Disease Control and Prevention reference procedures. Preparative ultracentrifugation was performed with the methods outlined in the Lipid Research Clinics methods manual. Serum or plasma was overlaid with normal saline (density, 1.006 g/mL) and centrifuged (Beckman Ultracentrifuge) at 40 000 rpm for 18 to 22 hours at 10°C to separate very-lowdensity lipoprotein cholesterol (VLDL-C) in the supernatant from LDL-C and high-density lipoprotein cholesterol (HDL-C) in the infranatant. The cholesterol concentration of the infranatant was measured. VLDL-C was calculated by subtracting the cholesterol concentration in the infranatant from the total cholesterol. Apo B-containing lipoproteins were precipitated from serum with 50-kDa dextran sulfate with magnesium ions (MgCl 2 ), followed by measurement of the cholesterol in the remaining HDL fraction. LDL-C was determined by subtracting the cholesterol concentration in the HDL fraction from the infranatant cholesterol. Non-HDL-C was calculated by subtracting HDL-C levels from total cholesterol levels. 
Statistical Analysis
Continuous variables were summarized with descriptive statistics. Categorical variables were summarized with counts and percentages. The analysis included all participants who received at least 1 dose of the study treatment and for whom both baseline and 180-day measurements were available. Individuals were analyzed on the basis of the group to which they were randomized and in whom paired measurements were available at baseline and at 180 days (modified intention to treat), in accordance with the prespecified statistical analysis plan. Percent change from baseline in lipid and lipoprotein parameters to day 180 (the primary efficacy time point) was analyzed with mixed-effect models for repeated measures; the model included days 30, 60, 90, 120, 150, and 180 (equal spacing), with day 180 as the primary time point and day 90 as the secondary time point. The analysis was carried out with the SAS proc mixed procedure with autoregressive variance structure, with treatment at each visit as a fixed effect and subjects as random effects. The analysis was adjusted for baseline value. The least-square means were calculated for each treatment at each visit. P values were adjusted for multiple comparisons with the Dunnett test for comparison across the 6 inclisiran and placebo groups. Data from the 1-dose and 2-dose strategies were independently analyzed.
Statistical significance was set at P=0.05 for a 2-sided test. No multiplicity adjustment was performed for the secondary end points in this phase 2 study. Waterfall plots were used to graphically display individual variation in response from baseline to day 180 for both percent and absolute changes in lipids and lipoproteins. Data on the time course are provided to day 210, which was the common end of study visit for all participants, allowing meaningful comparison of all lipid parameters. Apolipoproteins and Lp(a) data were not available beyond day 210.
Analyses were performed with SAS software, version 9.2 and higher (SAS Institute). Full details of the statistical plan have been reported previously.
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RESULTS
Of the 501 ORION-1 participants, 497 received at least 1 dose of the study drug or placebo. The mean age of participants was 63 years, 65% were male, 6% had heterozygous familial hypercholesterolemia, 69% had a history of ASCVD, 24% had diabetes mellitus, and their mean body mass index was 29 kg/m 2 ( Table 1) . At baseline, 73% of participants were on statin therapy (39% on high-intensity statins) and 31% were receiving ezetimibe. The percentage of participants who received ezetimibe monotherapy (ie, statin-intolerant patients) was 6.4%, whereas 24% received statin therapy in combination with ezetimibe. In total, 79% of participants with prior ASCVD received statin therapy; 41% received high-intensity statin therapy, and 13% of these patients were on high-intensity statin therapy plus ezetimibe. Baseline LDL-C was 116 mg/dL in the prior ASCVD group and 156 mg/dL in the group without prior ASCVD. Lipid and lipoprotein levels at baseline and day 180 are shown in Table 2 .
Non-HDL-C, Apo B, and Total Cholesterol
Statistically significant reductions in total cholesterol, LDL-C, non-HDL-C, and apo B were sustained at day 180 (the primary efficacy time point) in all single-dose and 2-dose groups. Specifically, the percent change in total cholesterol from baseline ranged between −18% and −27% in the single-dose groups and between −22% and −33% in the 2-dose groups (P<0.001 for all groups versus placebo; Figure I in the online-only Data Supplement); LDL-C changes ranged between −28% and −42% in the single-dose groups and between −36% and −53% in the 2-dose groups (P<0.001 for all groups versus placebo); non-HDL-C changes ranged between −25% and −37% in the single-dose groups and −32% and −46% in the 2-dose groups (P<0.001 for all groups versus placebo; Figures 1 and 2) ; and apo B changes ranged between −23% and −33% in the single-dose groups and −28% and −41% in the 2-dose groups (P<0.001 for all groups versus placebo; Figures 1 and 2 ). At day 210 (ie, 120 days after the second dose), mean apo B levels in the 300-mg 2-dose group were similar to the nadir achieved with a single dose (−39.3%; Figure 2 ).
Changes in LDL-C from baseline to day 240 have been previously reported. 5 The time course of changes in non-HDL-C and apo B closely tracked changes in LDL-C (Figures 1 and 2 ). Substantial reductions in both parameters were already apparent at the first measurement at day 14 in all dosing groups. Non-HDL-C and apo B levels continued to decline until ≈60 days after administration. Subsequently, the measured non-HDL-C and apo B values increased by ≈2% to 4% every 30 days relative to the prior measurement. Administration of a second dose of inclisiran on day 90 augmented the non-HDL-C and apo B reduction: reductions from baseline in non-HDL-C at day 150 ranged between −36% and −48% in the 2-dose groups compared with −31% to −45% reductions at day 60. Similarly, apo B reductions at day 150 ranged between −33% and −45% compared with reductions at day 60 of −29% to −41%.
All participants in the 300-mg 2-dose group had reductions in LDL-C, non-HDL-C, and apo B levels at day 180, which contrasted with the expected interindividual variation of these parameters in the placebo group (waterfall plots are shown in Figures . 5 The percentage of participants with apo B <80 or <100 mg/dL at day 180 in the 300-mg double-dose group was 78.0% and 89.8%, respectively. In contrast, only 24.6% and 49.2% of individuals in the placebo group attained these goals. Similarly, the percentage of participants with non-HDL-C <100 or <130 mg/dL at day 180 was 67.8% and 83.1%, respectively, in the 300-mg double-dose group compared with 11.5% and 37.7% of individuals in the placebo group. In the 300-mg single-dose group, 73.3% of participants still had apo B <80 mg/dL 180 days after administration, and 83.3% had apo B <100 mg/dL. The percentage of participants with non-HDL-C <100 and <130 mg/dL at day 180 in the 300-mg single-dose group was 61.7% and 78.3%, respectively.
At day 180, the percentage change in apo B and non-HDL-C in the placebo groups ranged from −39.9% to 46.2% and −46.2% to 46.7%, respectively. In contrast, for single-dose inclisiran 300 mg, the percentage change in apo B at day 180 ranged between −65.5% and 27.7% and in non-HDL-C ranged between −69.4% and 35.1%. The 300-mg double-dose regimen appeared to provide the most homogeneous apo B and non-HDL-C reductions, ranging from −70.3% to −4.8% and −75.1% to −8.3%.
Very-Low-Density Lipoprotein Cholesterol
At the primary efficacy time point (day 180), statistically significant reductions in VLDL-C were observed in the 300-and 500-mg single-dose groups (median reduction from baseline, −24% [P<0.01 versus placebo] and Smoking (current), n (%) 7 (11) 9 (15) 11 (18) 10 (15) 8 (13) 7 (11) 9 (14) 7 (12) Hypertension, n (%) 43 (66) 38 (63) 43 (69) 39 (60) 44 (72) 46 (74) 47 (75) 43 (70) Prior ASCVD, n (%) 46 (71) 43 (72) 48 (77) 37 (56) 46 (74) 43 (69) 41 (65) 43 (70) DM, n (%) 5 (8) 4 (7) 3 (5) 9 (14) 7 (11) 8 (13) 10 (16) 8 (13) FH, n (%) 1 (2) 6 (10) 2 (3) 7 (11) 3 (5) 3 (5) 3 (5) 3 (5) Primary prevention, n (%) 12 (18) 7 (12) 7 (11) 11 (17) 6 (10) 6 (10) 9 (14) 7 (11) Statin treatment, n (%) 46 (71) 50 (83) 46 (74) 45 (68) 48 (77) 44 (71) 41 (65) 45 (74) High-intensity statin, n (%) 27 (42) 31 (52) 23 (37) 23 (35) 22 (36) 29 (47) 23 (37) 21 (34) Ezetimibe and statin, n (%) 18 (28) 20 (33) 13 (21) 17 (26) 14 (23) 15 (24) 12 (19) 10 (16) Ezetimibe monotherapy, n (%) 2 (3. The time course of the changes in VLDL-C was broadly similar to that of LDL-C, apo B, and non-HDL-C (Figures 1 and 2 ). Reductions in VLDL-C were apparent in all dosing groups at the first measurement (day Apo indicates apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); PCSK9, proprotein convertase subtilisin/kexin type 9; and VLDL-C, very-low-density lipoprotein cholesterol.
*Plus-minus values are mean±SD. Numbers represent means (standard deviations) or medians (interquartile ranges). Data are presented for the modified intentionto-treat population, which consisted of all patients who underwent randomization, who received at least 1 dose of study agent, and for whom both baseline and day 180 LDL-C measurements were available. 14) and continued to decline until day 30, thereafter slowly returning to baseline. At day 60, the median VLDL-C reduction ranged between −14% and −24%; the comparable ranges at day 150 were between −8% and −19% for the single doses and −12% and −23% for participants who received a second dose at day 90.
In contrast to the homogeneous reductions in LDL-C, non-HDL-C, and apo B, there was substantial interindividual and temporal variability in the observed VLDL-C reductions (waterfall plots are shown in Figures 
Triglycerides
At the primary efficacy time point (day 180), statistically significant triglyceride reductions were observed in the 300-and 500-mg single-dose groups (−13% from baseline [P<0.01 versus placebo] and −12% [P<0.05], respectively) and in the 300-mg 2-dose group (−14% [P<0.05]). In contrast, there was no statistically significant effect on triglyceride levels at day 180 in the 200-mg single-dose group or in the 100-and 200-mg 2-dose groups. At day 210, the median change in triglycerides ranged between 0% and −12% in the single-dose groups and between −9% and −10% in the 2-dose groups.
At day 90, the median change from baseline ranged between 1% and −12% for all dosing groups; at day 150, the median reduction change ranged between −5% and −13% for the single-dose groups and between −5% and −18% for the 2-dose groups (plots of the time course of triglyceride reductions are shown in Figure XI in the online-only Data Supplement).
Similar to what was observed for VLDL-C, there was substantial interindividual variation in the change from baseline in triglyceride levels at day 180 both in absolute and in percentage terms in the placebo and all treatment groups (Figures XII-XV in the online-only Data Supplement).
HDL-C and Apo A1
At the primary efficacy time point (day 180), HDL-C levels were significantly increased in the 300-mg single- 
. Time course of the effect of inclisiran on apolipoprotein B (apo B), non-high-density lipoprotein (HDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and lipoprotein(a) (Lp[a]) levels up to day 210: single-dose regimens.
For apo B, non-HDL cholesterol, and VLDL cholesterol, data are presented as mean percent change from baseline ±95% CI. For Lp(a), data are presented as absolute changes from baseline (in milligrams per deciliter) ±95% CI. *For Lp(a), absolute changes are depicted to account for the large effect in percent terms among patients with very low baseline (BL) Lp(a) values.
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and 9% [P<0.01] for the 100-, 200-, and 300-mg 2-dose groups, respectively). Nonsignificant elevations in HDL-C were observed in the 200-and 500-mg single-dose groups. The corresponding ranges at day 210 were 6% to 7% in the single-dose groups and 7% to 11% in the 2-dose groups. Modest increases were also seen in apo A1 levels ( Figure XVI in the online-only Data Supplement). At day 180, the percentage change from baseline ranged between 3% and 4% in the singledose groups and between 6% and 9% in the 2-dose groups (P<0.05 versus placebo in the 200-and 300-mg groups but not in the other groups); at day 210, the apo A1 increases were 1% to 2% in the single-dose groups and 3% to 5% in the 2-dose groups. Changes in HDL-C were apparent at day 14, and HDL-C continued to increase until approximately day 150 after a single dose ( Figure XVII in the online-only Data Supplement). Of note, the effect of inclisiran on HDL-C appeared to outlast the effect on other lipid parameters. At day 90, the percentage change from baseline in HDL-C ranged between 5% and 12%; the corresponding ranges at day 150 were 6% to 9% in the single-dose groups and 8% to 9% in the 2-dose groups.
Lipoprotein(a)
The median Lp(a) reductions from baseline at the primary efficacy time point (day 180) were −14% to −18% in the single-dose groups and −15% to −26% in the 2-dose groups. The Lp(a) reduction did not reach statistical significance in any of the dosing groups. As shown in the waterfall plots in Figures 3 and 4 (double-dose regimens) and Figures XVIII and XIX in the online-only Data Supplement (single-dose regimens) and in the box-and-whisker plots in Figure XX in the online-only Data Supplement, there was substantial interindividual variation in the magnitude of the Lp(a) reductions. Despite the variation in the magnitude of the effect on Lp(a), ≈90% of participants in the 300-mg 2-dose group still had lower Lp(a) levels compared with baseline at day 180.
The time course of changes in Lp(a) tracked those of other apo B-containing lipid fractions (Figures 1  and 2) . At day 90, the median Lp(a) reductions ranged between −18% and −25%; the corresponding ranges at day 150 were −15% to −19% in the single-dose groups and −19% to −25% in the 2-dose groups. 
DISCUSSION
The ORION-1 trial demonstrated that reducing PCSK9 through the use of a novel siRNA therapeutic approach produces robust and prolonged LDL-C reduction in patients with elevated LDL-C despite receiving the maximum tolerated dose of a statin. The present prespecified analyses reveal (1) that a single-dose starting regimen of inclisiran reduces apo B, non-HDL-C, and VLDL-C over 210 days and that a 2-dose starting regimen 90 days apart provides additional lowering of these lipids; (2) that there was modest variability in the effects on LDL-C, apo B, and non-HDL-C at day 180, whereas there was a larger response variation for VLDL-C, triglycerides, and Lp(a); and (3) that the effects on all major lipids and lipoproteins were already apparent at day 14 after the first administration, that a second dose administered at day 90 (2-dose starting regimen) augmented the duration and magnitude of the apo B and non-HDL-C reductions, and that the effect attenuated slowly and linearly.
Response Variability
Statin therapy is the foundation of therapeutic ASCVD risk reduction, on the basis of the large body of evidence demonstrating its efficacy and safety. Nevertheless, variable response and noncompliance have been widely documented and seriously undermine the potential benefits of statin therapy. 11, 12 Although poor adherence likely underlies the majority of insufficient response to statin therapy in routine care, variability in response is also seen in the setting of clinical trials in which poor adherence is typically less pronounced and may be partially explained by biological factors such as genetic variants, sex, age, and body weight. 12, 13 In the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), 11% of participants did not have any LDL-C reduction on treatment with rosuvastatin 20 mg, and the percentage of individuals experiencing LDL-C reductions >35% was ≈70%.
14 In comparison, all ORION-1 participants in the 300-mg 2-dose group experienced reductions in LDL-C, apo B, and non-HDL-C, and ≈90% had LDL-C reductions >35%. In addition, in clinical trials, >40% of patients treated with high-intensity statin therapy fail to reach LDL-C levels <70 mg/dL. In ORION-1, only 15% of participants treated with high-intensity statin therapy in combination with 2 doses of inclisiran 300 mg failed to reach LDL-C levels <70 mg/dL. Thus, inclisiran could fill an important gap in the treatment of patients 
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who respond insufficiently to established therapies. It should be noted, however, that there were only 61 individuals in the 300-mg 2-dose group. Data on the response variability in clinical trials of PCSK9-inhibiting mAbs are limited. Although the development of the partially human mAb bococizumab was stopped because antidrug antibodies caused attenuation of effect over time, substantial variation in response was also observed among patients without antidrug antibodies. For example, 9% of bococizumab-treated patients who did not develop antidrug antibodies had no reduction in LDL-C in the SPIRE trials (The Evaluation of Bococizumab [PF-04950615;RN316] in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects). 15 The sources of this variation, as well as the degree of individual variation in response to other PCSK9-inhibiting mAbs, remain to be determined. It could be speculated that the homogeneous response to inclisiran compared with other lipid-lowering therapies, which was most pronounced in the 300-mg 2-dose group, is related to its mechanism of action-that is, direct inhibition at the level of synthesis of PCSK9. It is also possible that feedback loops that upregulate PCSK9 production are more adequately controlled by inclisiran.
Duration of Effect
The reductions in LDL-C, non-HDL-C, and apo B observed in ORION-1 were stable over time, and the mean LDL-C reduction was still >50% 4 months after the second administration of 300 mg inclisiran. Through modeling and available data on LDL-C to 1 year, the duration of effect observed in ORION-1 suggests that a 6-month maintenance regimen after a 2-dose starting regimen with dosing at days 1 and 90 may be an effective and convenient strategy to lower LDL-C, and this is the starting and maintenance dosing regimen currently being evaluated in the phase 3 clinical trial program of inclisiran (https://www.clinicaltrials.gov, identifiers NCT03399370, NCT03400800, and NCT03397121). A major limitation of statins is that they need to be taken daily, which is expected to be an important contributor to the widely documented poor adherence to statin therapy. It has been reported that approximately half of patients are no longer adherent to statin therapy 1 year after the initial prescription, and interrupted administration may adversely affect cardiovascular disease risk. [16] [17] [18] PCSK9-inhibiting mAbs need to be administered once or twice per month by self-injection, and medication adherence in routine care may be substantially <100%.
19 The potential benefit of the elimination of within-individual variability in LDL-C levels over time in individuals treated with inclisiran lies in the fact that fluctuations in on-treatment cholesterol are associated with higher cardiovascular disease risk, even after correction for therapy adherence, treatment effects, and attained LDL-C levels. 20 An infrequent dosing regimen, as may be feasible with inclisiran, could allow, for instance, the therapy to be administered by healthcare professionals and would therefore increase the likelihood of adherence with a larger proportion of patients achieving lipid goals. It is reasonable to assume that such differences may be even more pronounced in routine clinical practice as opposed to the controlled setting of clinical studies. The results of clinical outcome studies will demonstrate whether these theoretical benefits of inclisiran translate into improved cardiovascular disease outcomes.
Lipid and Lipoprotein Goal Attainment
Although the strong and causal relationship between LDL-C and ASCVD risk has been firmly established, apo B and non-HDL-C more adequately reflect ASCVD risk than LDL-C when LDL-C and apo B or non-HDL-C are discordant, as is commonly observed in patients with diabetes mellitus or the metabolic syndrome, who have high triglyceride levels and low HDL-C. [21] [22] [23] [24] [25] [26] [27] Discordance between LDL-C (ie, the amount of cholesterol in the low-density lipoprotein [LDL] fraction) and measures reflecting atherogenic lipoprotein particle numbers such as apo B can occur as a result of variation in the amount of cholesterol per LDL particle or variation in the number of apo B-containing lipoprotein other than LDL such as very-low-density lipoprotein. Measurement of LDL-C does not capture cholesterol carried in other atherogenic lipid fractions such as remnant cholesterol. Therefore, focusing solely on LDL-C reductions may lead to overestimation or underestimation of the clinical benefits of therapies if apo B levels are not reduced concordantly. It is thus reassuring that inclisiran robustly lowered apo B and non-HDL-C in ORION-1 and enabled the large majority of participants to attain guideline-recommended goals for these parameters.
Recent guidelines have introduced these targets in treatment recommendations. In ORION-1, 78.0% and 89.8% of participants in the 300-mg 2-dose group achieved the guideline-recommended apo B goals of <80 and <100 mg/dL for very-high-risk and high-risk patients at day 180, and 67.8% and 83.1% of participants achieved non-HDL-C levels <100 and <130 mg/ dL, respectively. 27, 28 Thus, inclisiran enabled a 3.2-fold increase in the percentage of patients achieving the apo B goal of <80 mg/dL compared with patients who received only statins and a 5.9-fold increase in the percentage of patients achieving the non-HDL-C goal of <100 mg/dL. All ORION-1 participants received the maximum tolerated lipid-lowering therapy. Overall, statin use and high-intensity statin use were comparable to what has been reported in the routine care setting (eg, 39% of participants received high-intensity statins), implying that many participants were unable to tolerate statins at doses appropriate for their level of ASCVD risk and thus did not receive guideline-recommended therapy. 29 
Intracellular Inhibition of PCSK9
The magnitude of the effect of inclisiran on all major lipids and lipoproteins as observed in ORION-1 was similar to that of PCSK9-inhibiting mAbs, suggesting that there are probably no clinically meaningful differences between the different approaches to PCSK9 inhibition. It should be noted, however, that the relatively small number of individuals treated with inclisiran to date precludes final conclusions. Experiments with cells and in animals, and particularly studies of individuals with variants in the PCSK9 gene and human kinetic studies, have confirmed that enhanced clearance of LDL particles, as well as its precursor lipid particles of LDL, is the key mechanism through which PCSK9 inhibition reduces cholesterol levels. However, these studies also demonstrated that the intracellular inhibition of PCSK9 may affect lipid and lipoprotein metabolism beyond modulation of LDL receptor expression. 6 For example, several lines of evidence suggest that PCSK9 may be involved in hepatic apo B production or secretion. Exploitation of an LDL receptor-independent effect of PCSK9 inhibition would be particularly beneficial in the treatment of patients with familial hypercholesterolemia, who have reduced LDL receptor functionality. 7, 10 Kinetic studies of PCSK9-inhibiting mAbs in normolipidemic individuals showed that extracellular inhibition of PCSK9 did not affect very-low-density lipoprotein secretion. In addition, patients with homozygous familial hypercholesterolemia without residual LDL receptor activity do not respond to PCSK9-inhibiting mAbs. 8, 9, 30 The similarity in the 20% to 25% VLDL-C reduction with inclisiran and PCSK9 mAbs suggests that the relevance of any possible effect of intracellular PCSK9 inhibition on apo B secretion is probably limited. Lipoprotein kinetic studies are required to determine whether small differences might still exist that perhaps also contribute to the sustained durability of effect of inclisiran compared with mAbs.
Effect of Inclisiran on Other Lipids and Lipoproteins
Inclisiran modestly increased HDL-C and apo A1, with an effect size comparable to PCSK9-inhibiting mAbs and statins. 1, 31 The mechanism and relevance of the effect on HDL-C remain to be determined, although any possible contribution of the effect on HDL-C and apo A1 to improved clinical outcomes is unlikely, given the failure to elicit clinical benefit of therapies that raise apo A1
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and HDL-C to a far greater extent. Of note, it appeared that the duration of the effect on HDL-C outlasted that of other lipid parameters. The mechanism to explain the prolonged effect on HDL-C is unclear, although it is noteworthy that a difference in the time course of changes in HDL-C and other lipid parameters has also been observed in studies of various other lipid-modifying agents such as niacin and cholesterylester transfer protein inhibitors. [32] [33] [34] [35] [36] Numerous studies have shown that Lp(a) is an independent risk factor and likely a causal factor for AS-CVD. 37 There was substantial interindividual variability in the observed Lp(a) reductions among patients treated with inclisiran, which probably explains the fact that Lp(a) reductions did not reach statistical significance in any of the treatment groups. Nonetheless, Lp(a) reductions were apparent in ≈90% of participants in the 300-mg 2-dose group. Numerically, the 26% median reduction at day 180 in the 300-mg 2-dose group was quite similar to the effect typically seen in trials of PCSK9 mAbs. 38 Thus, it appears as though inclisiran reduces Lp(a) in the majority of patients, although there seems to be a subset of patients who do not respond.
Neither the mechanism nor the clinical relevance of the Lp(a) reduction among PCSK9 inhibitor-treated patients has been firmly established. However, kinetic studies of PCSK9-mAbs suggest that the observed Lp(a) reductions are dependent on increased catabolism rather than reduced production of apo(a). 9 In vitro studies and the relationship between between gene-dose and Lp(a) levels in individuals with mutations in the LDL receptor or the APOB gene support a role for the LDL receptor. 38, 39 However, statin therapy generally does not affect Lp(a) levels despite potent upregulation of the LDL receptor.
CONCLUSIONS
The present analysis of the ORION-1 trial shows that inhibition of hepatic PCSK9 synthesis with the siRNA therapeutic inclisiran produces robust, sustained, and concordant reductions in apo B and non-HDL-C, as well as modest reductions in VLDL-C and triglycerides, while also modestly increasing HDL-C and apo A1 over 210 days. The magnitude of the effects on an array of lipids and lipoproteins is broadly comparable to that observed in clinical trials of PCSK9-inhibiting mAbs. The prolonged duration of effect of inclisiran supports a convenient maintenance dosing regimen such as biannual dosing. A 2-dose starting regimen 90 days apart and a subsequent 6-month maintenance regimen is being evaluated in 3 ongoing phase 3 clinical trials.
